Ignite Creation Date:
2024-05-05 @ 5:27 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00464646
Status:
COMPLETED
Last Update Posted:
2021-10-25
First Post:
2007-04-19
Brief Title:
Therapy With Bevacizumab BEV Epirubicin and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer
Sponsor:
NSABP Foundation Inc
Organization:
NSABP Foundation Inc
Organization Data
Organization:
NSABP Foundation Inc
Class:
NETWORK
Study ID:
NSABP FB-5
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
NSABP Foundation Inc
Lead Sponsor Class:
NETWORK
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Genentech Inc | INDUSTRY |
| International Drug Development Institute | OTHER |